医学
合生元
肠道疾病
梅德林
内科学
重症监护医学
普通外科
益生菌
遗传学
疾病
政治学
细菌
生物
法学
作者
Iva Hojsak,Sanja Kolaček,Walter Mihatsch,Alexis Mosca,Raanan Shamir,Hania Szajewska,Yvan Vandenplas,Chris H.P. van den Akker,Roberto Berni Canani,Ener Çağrı Dinleyici,Magnus Domellöf,Johannes B. van Goudoever,Alfredo Guarino,Pedro Gutiérrez‐Castrellón,Flavia Indrio,Rok Orel,Silvia Salvatore,Zvi Weizman
标识
DOI:10.1097/mpg.0000000000003568
摘要
Background: Synbiotics are a mixture comprising of live microorganisms and substrate(s) selectively utilized by host microorganisms that confers a health benefit on the host. There is an increasing number of studies investigating their role in different diseases and disorders. Aim: The purpose of this article is to provide recommendations for the use of synbiotics in the management of pediatric gastrointestinal disorders. The recommendations are developed by the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. Methods: From existing literature databases, we searched and appraised all systematic reviews and/or meta‐analyses, and subsequently published randomized controlled trials (RCTs) that compared the use of synbiotics, in all delivery vehicles and formulations, at any dose, compared to no synbiotics. Synbiotics which are part of infant formula were not assessed. The recommendations were formulated only if at least 2 RCTs that used a well‐defined synbiotic were available. Results: Based on the currently available evidence, no recommendation can be formulated in favor or against the use of evaluated synbiotic combination in the treatment of acute gastroenteritis, prevention of necrotizing enterocolitis, Helicobacter pylori infection, inflammatory bowel disease, functional gastrointestinal disorders, and allergy in infants and children. Conclusions: There is a need for more, well‐designed RCTs on the role of synbiotics in gastrointestinal disorders with the same outcome measures to enable the inter‐studies comparisons.
科研通智能强力驱动
Strongly Powered by AbleSci AI